41st EORTC –PAMM winter meeting: February 13th-15th, 2020 in Stockholmfebbraio 15, 2020
Our research program on Thoracic Cancers is a multifaceted effort designed to understand thoracic cancer biology, discover novel agents and improve treatment.
For our ongoing studies on mesothelioma we recently obtained a grant from the Mesothelioma Applied Research Foundation (US)
See: Press Release
Novel agents hold also great promise for lung cancer patients. A key development in cancer research over the past year is understanding how to rationally target the right treatments for the right patient in order to improve outcomes for all. We have therefore studied the biology of the epidermal growth factor receptor (EGFR) and how mutations (and polymorphisms) play a key role in explaining the uniquely strong responses seen when administering EGFR tyrosine kinase inhibitors to certain lung cancer patients. Now we are actively examining strategies to overcome both intrinsic and acquired resistance to anti-EGFR therapy.
Another major focus of our research effort has been pharmacogenetics of lung cancer. Similar to our studies with EGFR, the ultimate goal of this work is facilitating more rationale treatment selections for patients. Our group has also made key observations regarding the role of cytidine deaminase and outcome from cancer therapy. Clinical trials further examining this relationship are underway.